Liu Ke-Chun, Chen Yueh-Chen, Hsieh Chi-Fen, Wang Mu-Hui, Zhong Meng-Xun, Cheng Nai-Chen
Department of Surgery, National Taiwan University Hospital and College of Medicine, Taipei 100, Taiwan.
APL Bioeng. 2024 Oct 1;8(4):041501. doi: 10.1063/5.0225807. eCollection 2024 Dec.
Recent advances in scaffold-free three-dimensional (3D) culture methods have significantly enhanced the potential of stem cell-based therapies in regenerative medicine. This cutting-edge technology circumvents the use of exogenous biomaterial and prevents its associated complications. The 3D culture system preserves crucial intercellular interactions and extracellular matrix support, closely mimicking natural biological niches. Therefore, stem cells cultured in 3D formats exhibit distinct characteristics, showcasing their capabilities in promoting angiogenesis and immunomodulation. This review aims to elucidate foundational technologies and recent breakthroughs in 3D scaffold-free stem cell engineering, offering comprehensive guidance for researchers to advance this technology across various clinical applications. We first introduce the various sources of stem cells and provide a comparative analysis of two-dimensional (2D) and 3D culture systems. Given the advantages of 3D culture systems, we delve into the specific fabrication and harvesting techniques for cell sheets and spheroids. Furthermore, we explore their applications in pre-clinical studies, particularly in large animal models and clinical trials. We also discuss multidisciplinary strategies to overcome existing limitations such as insufficient efficacy, hostile microenvironments, and the need for scalability and standardization of stem cell-based products.
无支架三维(3D)培养方法的最新进展显著提高了再生医学中基于干细胞疗法的潜力。这项前沿技术避免了外源性生物材料的使用,并防止了其相关并发症。3D培养系统保留了关键的细胞间相互作用和细胞外基质支持,紧密模拟天然生物微环境。因此,以3D形式培养的干细胞表现出独特的特性,展示了它们在促进血管生成和免疫调节方面的能力。本综述旨在阐明3D无支架干细胞工程的基础技术和最新突破,为研究人员在各种临床应用中推进该技术提供全面指导。我们首先介绍干细胞的各种来源,并对二维(2D)和3D培养系统进行比较分析。鉴于3D培养系统的优势,我们深入探讨了细胞片和球体的具体制备和收获技术。此外,我们还探讨了它们在临床前研究中的应用,特别是在大型动物模型和临床试验中的应用。我们还讨论了多学科策略,以克服现有局限性,如疗效不足、恶劣的微环境以及基于干细胞的产品对可扩展性和标准化的需求。